Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 7INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Conditions

Warts 2

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × 2-Propanol × Clear all
NCT03691831 2020-10-27

A Study of A-101 Topical Solution for the Treatment of Common Warts

Aclaris Therapeutics, Inc.

Phase 3 Completed
502 enrolled 22 charts

Warts

NCT03687372 2020-10-05

Study of A-101 Topical Solution for the Treatment of Common Warts

Aclaris Therapeutics, Inc.

Phase 3 Completed
503 enrolled 22 charts

Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡